Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.

Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, July 21, 2026, 11:00-11:30 AM CT

Learning Objectives:
  • Explain how transparency and manufacturer partnerships improve quality, consistency, and decision-making confidence in specimen management.
  • Evaluate blood collection tubes beyond cost and commodity assumptions, incorporating clinical impact and risk into decision-making.
  • Assess the potential risk points when using a blood collection device that has not been cleared for a specific purpose.

Roundtable presenters Nick Fingland, PhD, PMP, Senior Director, R&D Operations and Science, BD, and Chris Farnsworth, PhD, D(ABCC), Section Head of Clinical Chemistry, Professor of Pathology and Immunology, Washington University School of Medicine.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

August 2024

Clinical pathology selected abstracts

August 2024—Social media, including websites and platforms such as Facebook, Instagram, and X (formerly Twitter), are a dominant way to consume news and entertainment and have significant societal impact. Social media use in medicine, including pathology, is widespread and has been associated with numerous benefits. The medical industry generally has encouraged the professional use of social media, despite its potential harm. The approaches of various medical disciplines to social media have included support for early adoption, publication of how-to guides, enthusiastic backing by professional organizations, and formulation of guidelines to temper usage. The authors conducted a study to identify motivating forces and premises that underpin physicians’ adoption of social media for professional uses.

Anatomic pathology selected abstracts

August 2024—Emerging data suggest a correlation between T1 bladder cancer subcategorization, or substaging, and oncological outcomes. The International Society of Urological Pathology held a 2022 consensus conference on issues in bladder cancer, in Basel, Switzerland, in which it tasked a working group with making recommendations for T1 subcategorization of transurethral bladder resections. To this end, the ISUP developed and circulated a survey to its membership querying approaches for subcategorizing T1 bladder cancer. The survey focused on clinical relevance, pathological reporting, and endorsement of T1 subcategorization in the daily practice of pathology. Approximately 40 percent of respondents to the pre-meeting survey indicated that they do not routinely report the T1 subcategory.

Molecular pathology selected abstracts

August 2024—Alzheimer disease is genetically intricate and involves rare and common genetic variants. Early-onset autosomal dominant Alzheimer disease (ADAD) is caused by mutations in the APP, PSEN1, and PSEN2 genes, while variants in numerous other genes contribute to the risk of developing late-onset Alzheimer disease, with APOE considered the most significant risk factor. APOE4 homozygotes face a lifetime risk of Alzheimer disease dementia of up to 60 percent by age 85, significantly higher than that of heterozygotes or noncarriers of the gene. The predictability of outcomes in APOE4 homozygotes has not been previously studied, limiting the application of statistical methods used in ADAD for APOE4 research. The predictable sequence of pathological, biomarker, and clinical changes in ADAD and Down syndrome has offered insights into Alz­heimer disease pathophysiology.

Q&A column

August 2024
Q. I have been tasked with doing a quality assurance review comparing automated differential results to the manual differential done on the same patient. Do you have recommendations regarding acceptable analytical criteria? Read answer.
Q. Can activated clotting time results handwritten by a perfusionist be sent to the laboratory to be entered into the laboratory information system? Read answer.

Newsbytes

August 2024—Aravindhan Sriharan, MD, is a supporter of digital pathology, but when it comes to assessing images, he prefers the feel and speed of a microscope. And his conversations with colleagues indicate many of them do too. “If I’m scrolling around a digital image, I can’t get the kind of speed, accuracy, and dexterity that I can on a physical microscope,” says Dr. Sriharan, dermatopathologist at Dartmouth Hitchcock Medical Center and assistant professor of pathology and laboratory medicine at Dartmouth Geisel School of Medicine.

Put It on the Board

August 2024—The Association for Molecular Pathology published in July a joint consensus recommendation on DPYD genotyping. The intent is to provide guidance to clinical laboratories and assay manufacturers that develop, validate, and/or offer clinical DPYD pharmacogenomic testing. “Testing for variants in the DPYD gene can help identify individuals who may be at increased risk for severe fluoropyrimidine-related toxicity,” Victoria Pratt, PhD, co-chair of the AMP PGx working group and director of scientific affairs for pharmacogenetics at Agena Bioscience, said in a July 22 statement announcing the publication.

Letters

August 2024—In a recent landmark decision, the Supreme Court of the United States overruled the longstanding Chevron doctrine, a judicial precedent that has been foundational to administrative law and regulatory practice for four decades. This decision has profound implications for regulations promulgated by the hundreds of federal agencies. For laboratory professionals, understanding this decision will be valuable in understanding how the landscape will change.

MARKETPLACE

TRENDING